Literature DB >> 22433827

Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Y Waerzeggers1, P Monfared, T Viel, A Faust, K Kopka, M Schäfers, B Tavitian, A Winkeler, A Jacobs.   

Abstract

A deeper understanding of the role of specific genes, proteins, pathways and networks in health and disease, coupled with the development of technologies to assay these molecules and pathways in patients, promises to revolutionise the practice of clinical medicine. Especially the discovery and development of novel drugs targeted to disease-specific alterations could benefit significantly from non-invasive imaging techniques assessing the dynamics of specific disease-related parameters. Here we review the application of imaging biomarkers in the management of patients with brain tumours, especially malignant glioma. In our other review we focused on imaging biomarkers of general biochemical and physiological processes related with tumour growth such as energy, protein, DNA and membrane metabolism, vascular function, hypoxia and cell death. In this part of the review, we will discuss the use of imaging biomarkers of specific disease-related molecular genetic alterations such as apoptosis, angiogenesis, cell membrane receptors and signalling pathways and their application in targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22433827      PMCID: PMC3473896          DOI: 10.1259/bjr/66405626

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  108 in total

1.  Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.

Authors:  Bart Cornelissen; Veerle Kersemans; Ingrid Burvenich; Ruth Oltenfreiter; Jean-Luc Vanderheyden; Otto Boerman; Christophe Vandewiele; Guido Slegers
Journal:  Nucl Med Commun       Date:  2005-02       Impact factor: 1.690

Review 2.  Genetic and hypoxic regulation of angiogenesis in gliomas.

Authors:  Balveen Kaur; Chalet Tan; Daniel J Brat; Dawn E Post; Erwin G Van Meir
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

3.  PET of vascular endothelial growth factor receptor expression.

Authors:  Weibo Cai; Kai Chen; Khalid A Mohamedali; Qizhen Cao; Sanjiv S Gambhir; Michael G Rosenblum; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-12       Impact factor: 10.057

4.  18F-labelled annexin V: a PET tracer for apoptosis imaging.

Authors:  Yoshihiro Murakami; Hiroyuki Takamatsu; Junichi Taki; Mitsuyoshi Tatsumi; Akihiro Noda; Rikiya Ichise; Jonathan F Tait; Shintaro Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe.

Authors:  Shanta M Messerli; Shilpa Prabhakar; Yi Tang; Khalid Shah; Maria L Cortes; Vidya Murthy; Ralph Weissleder; Xandra O Breakefield; Ching-Hsuan Tung
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

7.  In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response.

Authors:  Marina Kartachova; Rick L M Haas; Renato A Valdés Olmos; Frank J P Hoebers; Nico van Zandwijk; Marcel Verheij
Journal:  Radiother Oncol       Date:  2004-09       Impact factor: 6.280

8.  Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice.

Authors:  Inna Serganova; Michael Doubrovin; Jelena Vider; Vladimir Ponomarev; Suren Soghomonyan; Tatiana Beresten; Ludmila Ageyeva; Alexander Serganov; Shangde Cai; Julius Balatoni; Ronald Blasberg; Juri Gelovani
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Authors:  Shyhmin Huang; Eric A Armstrong; Sergio Benavente; Prakash Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

Authors:  L Pukac; P Kanakaraj; R Humphreys; R Alderson; M Bloom; C Sung; T Riccobene; R Johnson; M Fiscella; A Mahoney; J Carrell; E Boyd; X T Yao; L Zhang; L Zhong; A von Kerczek; L Shepard; T Vaughan; B Edwards; C Dobson; T Salcedo; V Albert
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.